INTRODUCTION
A sustained-release dosage form is defined as "any drug or dosage form modification thatprolongs the therapeutic activity of the drug" 1 . Development of oral sustained release (SR) tablets of highly water soluble drugs or bioactives has always been a challenge and therefore, opportunity for formulation scientist. Most of these drugs if not formulated properly, may be released at a faster rate resulting in exceeding the maximum therapeutic levels and hence will lead to toxic side effects. Sustained delivery of such drugs ensures improved drug delivery and patient compliance, greater safety and efficacy, desired release kinetics and helps in maintaining the plasma drug concentration within the therapeutic window for extended period of time 2, 3. Lipids like glycerides are a family of excipients which have generated considerable interest in the preparation of oral dosage forms. Some glycerides such as Compritol ATO 888 (glyceryl behenate), Precirol ATO 5 (glyceryl palmitostearate) can be used for the preparation of sustained release dosageforms 5 . The esterification of glycerol by long chain fatty acid gives them a pronounced hydrophobic character with a low HLB value of 2 6 . Several techniques including melt granulation 7 , melt pelletization 8 , hot melt extrusion 9 and hot melt coating 10 have been used to obtain sustained release dosage forms from glycerides-based formulations.
Melt granulation (MG) is a solvent-free process which involves the use of a substance that melts at a relatively low temperature. This substance can be added in the molten form over the substrate or in the solid form, which is then heated above its melting point. The substance acts as a liquid binding agent, and the technique does not require the use of organic solvents.
Moreover, in melt granulation drying is not necessary and thus, the process is less consuming in terms of time and energy compared to other methods 4 . Sustained release matrix tablets have been produced with Compritol ATO 888 & Precirolby various methods including MG 11 , Co-processing and direct compression (DC) 12. Nateglinide, N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine] is a phenylalanine derivative lackingeither a sulfonylurea or benzamido moiety, which can restore the physical insulin secretion pattern lost in type 2 diabetes mellitus patients with postprandial hyperglycemia. Pharmacologically, nateglinide reportedly acts on pancreatic cells via the closure of the adenosine triphosphate-sensitive potassium channels by binding to sulphonylurea receptor subunits causingcell depolarization, calcium influx, and insulin release.The drug has a rapidonset and short duration of insulinotropic action (t½ is _1.5 hours and Tmax is_0.5-1.0 hour after dosing).
MATERIALS AND METHODS

Materials
Nateglinide was a gift from Pure chem, Bharuch, India while Compritol ATO 888 and Precirolwere obtained free of charge from Gattefosse SAS India. Di-Calcium phosphate, magnesium stearate, Aerosil 200, concentrated hydrochloric acid, sodium hydroxide and potassium dihydrogen phosphate were purchased from SD Fine chemicals, Mumbai, India. Distilled water (D.W.)was prepared freshly whenever required. Other chemicals and reagents used were of analytical grade.
Methods
Preparation of Nateglinide matrix tablets
Preparation of wax matrix tablets was done by three methods: Melt granulation, Co-processing and Direct compression as follows.
Identification of drug:
The obtained sample was examined by infrared absorption spectral analysis and was compared with the reference standard IR spectrum of API. Also UV spectrum was taken to identify the compound based on λ max and peak shape.
Organoleptic characteristics:
The color, odour and taste of the drug were characterized and recorded using descriptive terminology.
Solubility of drug:
The solubility of Drug was determined as per BCS. The solubility was checked in 250 ml of 0.01N HCl with 0.5% SLS and buffers within pH range 2 -8. The highest amount of dose was accurately weighed and transferred in individual volumetric flask containing different solutions and sonicate for 30 minutes. Interpretation was done based on BCS classification which states that drug is BCS class II.
Pre compression parameters :
a) Angle of repose : Angle of repose of the granules will be measured by the fixed height method. The powder sample equivalent to 10g will be accurately weighed, will fill in a 50 ml graduated cylinder, the powder will be levelled & the unsettled volume (Vi) will be noted. The bulk density will be calculated in g/cm3 by the formula. An in-vitro dissolution study will be carried out in
• Dissolution medium: 0.5% sodium lauryl sulphate (SLS) in 900 ml of Phosphate buffer (pH 6.8) with type II paddle.
• Temperature: 37±0.5 . C
• Stirring speed of Paddle:50rpm
• Time Point(hr): 1,2,3,4,5,6,7,8,9,10,11,12
• Sample amount: 5ml
• Volume: 900ml
Method of preparation:
Melt granulation method: The waxes(Compritol 888 ATO& Precirol ATO 5) was melted in a porcelain dish over a water bath maintained at 75-80°C for 3 min and Nateglinide was gradually added with continuous stirring until uniformly mixed. The molten mixture was allowed to cool and solidify at room temperature crushed in a mortar and passed through a 40# sieve. The granules were compressed into flat-faced tablet using multi-station rotary tablet compression machine (Krishna engineering Pvt. Ltd. India) at a constant compression force.
Evaluation of drug -Excipient interaction:
The pure drug, wax and the matrix tablet formulation were subjected to IR spectroscopy using FT-IR spectrophotometer. Their spectra were obtained over the wave number range of 4000 -400 cm -1 .
In-vitro drug release:
In vitro release studies were conducted using USP type II paddle apparatus (VDA-6D USP Std -VEEGO) run at 50 rpm. The buffer was kept at thermostatically controlled temperature of 37±0.5°C. The test was carried out in 900 ml of 0.01 M HCl for 2 h and then replaced with phosphate buffer (pH 6.8) as the dissolution medium for another 10 h. The pH change of medium was effected by adding 4.32g of sodium hydroxide and 6.08 g of potassium dihydrogen phosphate dissolved in 5 ml water to the previous acidic medium (0.1 M HCl) (17) . Five milliliters samples were withdrawn at the time intervals of 1, 2, 3, 4, 5, 6….12 and replaced with equal volume of fresh dissolution medium. The samples were filtered through 0.45 µm filter and analyzed for drug content at 218 nm by UV spectrophotometer. 
Formulation:
RESULTS
Interaction between drug and wax was checked by FT-IR Spectroscopy. The study showed that Precirol ATO 5 is an appropriate waxy matrix former for sustained release of low watersoluble drug such as Nateglinide.MG technique fits completely into the predetermined parameter and criteria whereas, other two techniques lack behind.
Sustained release profiles can be achieved by any of three methods using Precirol ATO 5 at higher proportion but MG technique achieved 12 h release profile with lesser amount of was as compare to other methods. Formulation F13 was given 94.55% drug release in 12h which was optimizing batch. 
